Angioplasty.Org
Most Popular Angioplasty Web Site
   
supported by Volcano Corporation
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Company Increases Revenue Guidance for 2008

external sites:
Volcano Corporation

May 7, 2008 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the first quarter of fiscal 2008.

For the quarter ended March 31, 2008, Volcano reported revenues of $36.6 million, a 24 percent increase over revenues of $29.6 million in the same period a year ago. The company said IVUS disposable revenues increased 30 percent versus the first quarter of 2007, reflecting the growth of its installed base and broader IVUS adoption.

For the first quarter of 2008, the company reported a net loss on a GAAP basis of $2.3 million, or $0.05 per share. Included in this loss is $2.9 million in due diligence, legal and accounting expenses related to an acquisition that was not consummated. In the first quarter of 2007, the company reported GAAP net income of $1.7 million, or $0.04 per diluted share.

Excluding the aforementioned due diligence costs, stock-based compensation expense and in-process research and development expenses totaling $5.1 million, Volcano had non-GAAP net income of $2.8 million, or $0.06 per diluted share. In the first quarter of 2007, excluding stock-based compensation expense of $1.2 million, Volcano had net income of $2.9 million, or $0.07 per diluted share. Weighted average diluted shares at the end of the quarter were 47.0 million versus 41.7 million a year ago, reflecting the impact of the company's equity offering that was completed in the fourth quarter of 2007. A reconciliation of the company's GAAP and non-GAAP results can be found in today's earnings news release on the company's website at http://www.volcanocorp.com.

"Volcano began 2008 with strong momentum by generating excellent revenue growth with our IVUS offerings and in our major geographies. Our IVUS disposable revenues were particularly strong, with year-over-year increases of 43 percent in Japan, 23 percent in the U.S. and 27 percent in Europe," said Scott Huennekens, president and chief executive officer.

"In addition, we have a solid pipeline of orders from customers awaiting the availability of IVUS systems with new features that we began shipping in the second quarter. Market adoption of IVUS continues to grow, driven by the growing volume of data demonstrating its value, our innovative and industry-leading technology that makes IVUS faster, easier and simpler to use and our effective sales, marketing and distribution programs. In addition, we are benefitting from an increasingly favorable environment for percutaneous coronary intervention (PCI) and stenting procedures," he continued.

"During the first quarter, we enhanced our technology advantage with the formal launch in the U.S. and Europe of our Revolution rotational catheter and FFR (fractional flow reserve) on the s5 family of IVUS consoles at the American College of Cardiology meeting. Full market release shipments are expected to begin in the current quarter. We are now the only IVUS company offering both phased array and rotational catheters in a single integrated console. In Japan, we received regulatory approval for the s5 tower last week and are on schedule for the full market release of the Revolution on the s5 family in the third quarter. In addition, we announced a new collaboration with Royal Philips Electronics under which they will resell Volcano-branded s5i IVUS systems and accessories alongside the Philips Allura Xper FD X-ray systems. We will continue to leverage this partnership, as well as those we have established with other leading cath lab equipment and stent companies, in our efforts to increase the rate of integrated lab adoption and win market share."

Volcano also said its product development programs remain on track, including the expected commercial launch in the second half of 2009 of its first image-guided therapy offering, a balloon and IVUS on the same catheter. Volcano also expects U.S. and European regulatory approval in the second half of 2009 for its initial Optical Coherence Tomography product incorporating the technology that the company acquired with its purchase of CardioSpectra at the end of 2007.

"Our new product initiatives are designed to offer a variety of modalities built around our s5i offering and to position Volcano to address a number of very sizeable therapy markets with innovative platform technologies," Huennekens noted. "We will also continue to explore strategic opportunities that provide offerings for our existing customer base and meet our growth rate, gross margin and valuation objectives," he added.

Guidance for 2008
The company updated its prior guidance for 2008. Volcano said it now expects revenues for the year will be in the range of approximately $164-$168 million. This compares with prior guidance of $158-$162 million, and represents an increase of approximately 26-29 percent over revenues in 2007. Gross margin is expected to be in the range of 60-61 percent, with the company expecting to exit 2008 with margins in the range of 63-64 percent. Operating expenses, including stock-based compensation, the $2.9 million in due diligence expense recorded in the first quarter, and approximately $3.1 million of intangible amortization, are expected to be 65-66 percent of revenues.

On a GAAP basis, the company expects to report a net loss of approximately $0.06-$0.10 per share. This compares to prior guidance for a net loss of $0.02-$0.04 per share. The decrease in guidance for earnings per share, despite the expected increase in revenues, reflects the due diligence expense, reduced interest income due to declining interest rates, increased sales and marketing expenses related to the revenue increase and increased research and development spending on programs to accelerate the commercialization of new products. The company expects to begin being profitable on a GAAP basis in the fourth quarter. Excluding stock-based compensation expense of approximately $10.0 million, due diligence costs and in-process research and development, Volcano expects to report non-GAAP net income of $0.16-$0.20 per diluted share. This compares with prior guidance for net income on this basis of $0.16-$0.18 per diluted share. Weighted average shares outstanding in 2008 are expected to be approximately 47.7 million basic shares and 50.4 million shares on a diluted basis.

Conference Call
The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (719) 325-4897, passcode 9694232, or via the company's website at http://www.volcanocorp.com. Please dial in or access the website 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available until May 16 at (719) 457-0820, passcode 9694232, and via the company's website.

Volcano Corporation
Volcano Corporation (Nasdaq: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 3,300 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.

Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock-based compensation is a non-cash expense, in-process research and development relates to the costs associated with the December 2007 acquisition of CardioSpectra, Inc. and the acquisition due diligence costs incurred in the first quarter of 2008 are not reflective of our core operating activities. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should note that the non-GAAP financial measures used by the company may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as those of other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's financial guidance for 2008, regulatory approvals and the impact of obtaining regulatory approvals, market adoption of the company's technology, the impact of clinical and other technical data, the safety and efficacy of the company's products, the success and timing of product development and clinical trial programs, growth strategies and market development, product sales and use and merger and acquisition activities. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.



                             VOLCANO CORPORATION
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                (in thousands)
                                 (Unaudited)

                                                 March 31,        December 31,
                                                   2008              2007
     Assets
     Current assets:
       Cash and cash equivalents                 $132,572          $122,913
       Short-term available-for-sale
        investments                                55,539            66,205
       Accounts receivable, net                    25,293            27,976
       Inventories                                 22,399            21,243
       Prepaid expenses and other current
        assets                                      3,979             3,997
          Total current assets                    239,782           242,334
     Restricted cash                                  376               365
     Property and equipment, net                   14,814            13,692
     Intangible assets, net                         8,641             9,385
     Other non-current assets                         804               798
                                                 $264,417          $266,574

     Liabilities and Stockholders' Equity
     Current liabilities:
       Accounts payable                           $10,051           $11,077
       Accrued compensation                         8,250             9,083
       Accrued expenses and other current
        liabilities                                 6,326             6,600
       Deferred revenues                            5,796             5,360
       Current maturities of long-term debt            58               120
          Total current liabilities                30,481            32,240
     Long-term debt                                    78                78
     Deferred license fee                           1,063             1,125
     Other                                            181               194
          Total liabilities                        31,803            33,637
     Stockholders' equity                         232,614           232,937
                                                 $264,417          $266,574



                             VOLCANO CORPORATION
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                    (in thousands, except per share data)
                                 (Unaudited)

                                                  Three Months Ended March 31,
                                                     2008              2007

     Revenues                                      $36,647           $29,579
     Cost of revenues                               13,629            10,865
     Gross profit                                   23,018            18,714
     Operating expenses:
           Selling, general and administrative      22,059            12,584
           Research and development                  5,637             4,688
           In-process research and development         175                 -
           Amortization of intangibles                 773               786
             Total operating expenses               28,644            18,058
     Operating income (loss)                        (5,626)              656
       Interest income                               1,833             1,195
       Interest expense                                 (4)              (89)
       Exchange rate gain                            1,679               122
         Income (loss) before provision for income
          taxes                                     (2,118)            1,884
       Provision for income taxes                      208               210
     Net income (loss)                             $(2,326)           $1,674
     Net income (loss) per share - basic            $(0.05)            $0.04
     Net income (loss) per share - diluted          $(0.05)            $0.04
     Weighted-average shares outstanding - basic    47,030            37,964
     Weighted-average shares outstanding - diluted  47,030            41,685



                             VOLCANO CORPORATION
            RECONCILIATION OF GAAP AND NON-GAAP OPERATING RESULTS
                    (in thousands, except per share data)
                                 (Unaudited)

                                    Three Months Ended March 31, 2008
                                                In-process Acquisition
                                    Stock-based  research     due
                             GAAP   compensation    and     diligence Non-GAAP
                            results   expense   development  costs     results

     Revenues               $36,647        $-       $-          $-    $36,647
     Cost of revenues        13,629      (191)       -           -     13,438
     Gross profit            23,018       191        -           -     23,209
     Operating expenses:
        Selling, general
         and
         administrative      22,059    (1,501)       -      (2,878)    17,680
        Research and
         development          5,637      (369)       -           -      5,268
        In-process
         research and
         development            175         -     (175)          -          -
        Amortization of
         intangibles            773         -        -           -        773
          Total operating
           expenses          28,644    (1,870)    (175)     (2,878)    23,721
     Operating loss          (5,626)    2,061      175       2,878       (512)
       Interest income        1,833         -        -           -      1,833
       Interest expense          (4)        -        -           -         (4)
       Exchange rate gain     1,679         -        -           -      1,679
         Income (loss)
          before provision
          for income taxes   (2,118)    2,061      175       2,878      2,996
       Provision for
        income taxes            208         -        -           -        208
     Net income (loss)      $(2,326)   $2,061     $175      $2,878     $2,788
     Net income (loss)
      per share - basic      $(0.05)    $0.04    $0.00       $0.06      $0.06
     Net income (loss)
      per share -
      diluted                $(0.05)    $0.04    $0.00       $0.06      $0.06
     Weighted-average
      shares outstanding
      - basic                47,030                                    47,030
     Weighted-average
      shares outstanding
      - diluted              47,030                                    49,698



                                    Three Months Ended March 31, 2007
                                                In-process Acquisition
                                    Stock-based  research     due
                             GAAP   compensation    and     diligence Non-GAAP
                            results   expense   development  costs     results

     Revenues               $29,579        $-       $-          $-    $29,579
     Cost of revenues        10,865      (112)       -           -     10,753
     Gross profit            18,714       112        -           -     18,826
     Operating expenses:
        Selling, general
         and
         administrative      12,584      (923)       -           -     11,661
        Research and
         development          4,688      (208)       -           -      4,480
        Amortization of
         intangibles            786         -        -           -        786
          Total operating
           expenses          18,058    (1,131)       -           -     16,927
     Operating income           656     1,243        -           -      1,899
       Interest income        1,195         -        -           -      1,195
       Interest expense         (89)        -        -           -        (89)
       Exchange rate gain       122         -        -           -        122
         Income before
          provision for
          income taxes        1,884     1,243        -           -      3,127
       Provision for
        income taxes            210         -        -           -        210
     Net income              $1,674    $1,243       $-          $-     $2,917
     Net income per
      share - basic           $0.04     $0.03       $-          $-      $0.08
     Net income per
      share - diluted         $0.04     $0.03       $-          $-      $0.07
     Weighted-average
      shares outstanding -
      basic                  37,964                                    37,964
     Weighted-average
      shares outstanding -
      diluted                41,685                                    41,685


Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial information as defined by the U.S. Securities and Exchange Commission Regulation G. Pursuant to the requirements of this regulation, a reconciliation of this non-GAAP financial information to our financial statements as prepared under generally accepted accounting principles in the United States (GAAP) is included in this press release. Non-GAAP financial measures provide an indication of our performance before certain charges. Our management believes that in order to properly understand our short-term and long-term financial trends, investors may wish to consider the impact of these charges. These charges result from facts and circumstances that vary in frequency and/or impact on continuing operations. Our management believes that these items should be excluded when comparing our current operating results with those of prior periods as stock- based compensation is a non-cash expense, in-process research and development relates to the costs associated with the December 2007 acquisition of CardioSpectra, Inc., and the acquisition due diligence costs incurred in the first quarter of 2008 are not reflective of our core operating activities. In addition, our management uses results of operations before certain charges to evaluate the operational performance of the company and as a basis for strategic planning. Investors should note that the non-GAAP financial measures used by the company may not be the same non-GAAP financial measures, and may not be calculated in the same manner, as those of other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP.



                             VOLCANO CORPORATION
                               REVENUE SUMMARY
                                (in millions)
                                 (Unaudited)

                                  Q1 '08      Q1 '07    Growth %
    IVUS Systems:
      United States                $3.8        $3.7         1%
      Japan                         0.9         0.7        32%
      Europe                        1.2         0.8        47%
      Rest of World                 0.5         0.6       -15%
    Total IVUS Systems             $6.4        $5.8         9%

    IVUS Disposables:
      United States               $11.6        $9.4        23%
      Japan                         8.8         6.1        43%
      Europe                        4.0         3.2        27%
      Rest of World                 0.8         0.6        31%
    Total IVUS Disposables        $25.2       $19.3        30%

    FM:
      United States                $1.9        $1.6        19%
      Japan                         0.2         0.7       -69%
      Europe                        1.5         1.2        26%
      Rest of World                 0.1         0.2       -14%
    Total FM                       $3.7        $3.7         2%

    Other                           1.3         0.8        71%
        Total                     $36.6       $29.6        24%

Source: Volcano Corporation